Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2019 Results Conference Call November 5, 2019 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Vice President of Clinical Development Conference Call Participants Alethia Young - Cantor Fitzgerald Kelsey Goodwin - Guggenheim Securities Ben Burnett - Stifel Matt Biegler - Oppenheimer Amanda Murphy - BTIG Biren Amin - Jefferies Jim Birche ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEU ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2019 Earnings Conference Call August 6, 2019 5:00 PM ET Corporate Participants Scott Wolchko - President and Chief Executive Officer Conference Call Participants Alethia Young - Cantor Kelsey Goodwin - Guggenheim Ted Tenthoff - Piper Jaffray Matthew Biegler - Oppenheimer Biren Amin - Jefferies Mara Goldstein - Mizuho Nick Abbott - Wells Fargo Daina Graybosch - SVB Leerink Operator Welcome to the Fate Therapeutics Second Quarter 2019 Financial Results Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of incorp ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2019 Results Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Scott Wolchko - President and CEO Dr. Dan Shoemaker - Chief Scientific Officer Conference Call Participants David Nierengarten - Wedbush Edward Tenthoff - Piper Jaffray Biren Amin - Jefferies Daina Graybosch - SVB Leerink Nick Abbott - Wells Fargo Operator Welcome to the Fate Therapeutics First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a liste ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (IRS Employer Identification No.) 92121 Delaware 65-13115 ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2018 Results Conference Call March 5, 2019 5:00 PM ET Company Participants Scott Wolchko - President and CEO Dr. Dan Shoemaker - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Jaffary Kripa Devarakonda - Citi Yanan Zhu - Wells Fargo Biren Amin - Jefferies Matt Biegler - Oppenheimer Reni Benjamin - Raymond James Operator Welcome to the Fate Therapeutics Fourth Quarter 2018 Financial Results Conference Call. At this time, all participants ar ...

Table of Contents Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ or No ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio ...